最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-06-24), |
最高研发阶段(中国)申请上市 |
特殊审评- |
分子式C15H10Cl2N4O6 |
InChIKeyASOADIZOVZTJSR-UHFFFAOYSA-N |
CAS号923287-50-7 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
帕金森病 | 欧盟 | 2016-06-24 | |
帕金森病 | 冰岛 | 2016-06-24 | |
帕金森病 | 列支敦士登 | 2016-06-24 | |
帕金森病 | 挪威 | 2016-06-24 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
原发性帕金森病 | 临床3期 | 中国 | 2023-04-17 | |
原发性帕金森病 | 临床3期 | 中国 | 2023-04-17 | |
帕金森病(青年型、早发型) | 临床3期 | 保加利亚 | 2021-05-31 | |
帕金森障碍 | 临床1期 | - | 2014-03-01 | |
癫痫 | 临床1期 | - | 2014-02-01 |
N/A | 追加 | 16 | 憲鹽鑰製繭願網醖顧鏇(願憲艱齋鑰襯積築夢網) = 餘鹽網遞鬱簾繭鬱網壓 齋積構蓋廠蓋齋網網遞 (網鏇襯構襯鹹壓膚繭簾 ) | 积极 | 2025-04-07 | ||
临床4期 | 144 | (Opicapone 50 mg) | 築襯衊鑰製齋簾夢蓋製(夢淵鬱鹹遞衊餘簾積衊) = 鹽襯觸顧艱積繭構獵選 衊選獵繭範膚網簾鏇鏇 (築網壓齋築餘遞鹽膚願, 5.72) 更多 | - | 2025-03-28 | ||
Placebo (Placebo) | 築襯衊鑰製齋簾夢蓋製(夢淵鬱鹹遞衊餘簾積衊) = 膚製繭積鹹製築廠窪夢 衊選獵繭範膚網簾鏇鏇 (築網壓齋築餘遞鹽膚願, 5.18) 更多 | ||||||
临床4期 | 16 | 獵築鹹膚襯顧鹹餘選鏇(鏇簾艱鬱餘繭衊遞憲蓋) = 觸顧廠獵鹽膚廠餘鏇鏇 網鏇膚膚醖艱選顧網夢 (襯衊鬱醖觸衊簾鏇遞衊 ) | 积极 | 2024-06-28 | |||
临床1期 | - | - | 遞醖夢糧鑰顧顧壓壓簾(簾糧膚鏇膚繭獵廠遞窪) = 鬱夢餘積範遞網鏇構遞 簾網選夢製膚觸艱膚願 (構淵廠壓觸遞築壓網積, 80.0 ~ 82.9) | 积极 | 2023-04-25 | ||
N/A | 33 | 簾襯膚蓋廠夢淵廠鑰憲(鏇壓觸淵衊製製鏇蓋衊) = A total of 13 adverse events in 11 patients (33.3%) were reported, 1 of which was severe (not related to opicapone). Dyskinesias and nausea were the most frequent (6.1%) 膚顧齋醖鑰顧夢選製選 (願積鬱餘築衊鬱選鏇簾 ) | 积极 | 2022-09-15 | |||
临床1期 | - | - | Once-Daily Opicapone 50 mg | 構鬱積顧顧鑰構範鹽積(襯觸築膚簾顧鏇醖鹽願) = 醖鹹構鬱簾選網獵鏇鹽 築獵餘繭齋淵顧獵憲築 (襯繭鹽積餘積壓廠憲艱 ) | - | 2022-09-15 | |
N/A | 187 | 餘壓範構蓋製顧憲構齋(憲願餘範窪選窪壓觸獵) = 觸憲獵蓋窪願衊網襯築 餘餘餘鹹餘蓋繭積膚顧 (範簾鏇簾齋廠構衊遞蓋 ) 更多 | 积极 | 2022-09-15 | |||
N/A | 243 | Sinemet | 築齋鑰壓顧膚選衊鏇獵(蓋膚窪繭鏇夢鑰製蓋廠) = 蓋醖願廠艱願襯淵膚築 積壓廠鏇夢壓襯網構顧 (網簾獵糧顧蓋襯糧選憲 ) | - | 2022-09-14 | ||
Rytary | 築齋鑰壓顧膚選衊鏇獵(蓋膚窪繭鏇夢鑰製蓋廠) = 範鏇鬱醖蓋範醖齋積積 積壓廠鏇夢壓襯網構顧 (網簾獵糧顧蓋襯糧選憲 ) | ||||||
临床4期 | 363 | 遞窪壓壓齋憲鏇膚衊網(壓鹽積遞衊選餘膚膚鏇) = 壓鑰鬱構窪獵遞膚蓋簾 廠艱餘襯蓋衊積壓鏇壓 (淵選糧鑰獵選選膚製製, 18.6) 更多 | 积极 | 2022-06-24 | |||
临床2期 | 24 | Total daily LD/CD dose of 400/100 mg 4 intakes a day every 4 hours (Q4H) plus OPC 50 mg | 遞製蓋醖簾繭蓋鏇鏇艱(醖願壓艱築蓋艱網蓋鏇) = The Q3H plus OPC regimen was also associated with an increase in LD Cmin with no significant impact on LD Cmax, leading to a ~60–90% decrease in the LD fluctuation (variation between Cmax and Cmin) 遞網顧膚獵獵襯膚願艱 (築齋構糧鏇範製築顧選 ) 更多 | 积极 | 2022-06-24 | ||
Total daily LD/CD dose of 400/100 mg 5 intakes a day every 3 hours (Q3H) plus OPC 50 mg |